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Abstract
Transcription factors (TFs) bind specific sequences in promoter-proximal and distal DNA 
elements in order to regulate gene transcription. RNA is transcribed from both of these DNA 
elements, and some DNA-binding TFs bind RNA. Hence, RNA transcribed from regulatory 
elements may contribute to stable TF occupancy at these sites. We show that the ubiquitously 
expressed TF YY1 binds to both gene regulatory elements and also to their associated RNA 
species genome-wide. Reduced transcription of regulatory elements diminishes YY1 occupancy 
whereas artificial tethering of RNA enhances YY1 occupancy at these elements. We propose that 
RNA makes a modest but important contribution to the maintenance of certain TFs at gene 
regulatory elements and suggest that transcription of regulatory elements produces a positive 
feedback loop that contributes to the stability of gene expression programs.
Active promoters and enhancer elements are transcribed bi-directionally (Fig. 1A) (1–3). 
Although various models have been proposed for the roles of RNA species produced from 
these regulatory elements, their functions are not fully understood (4–13). Evidence that 
some DNA-binding transcription factors (TFs) also bind RNA (14, 15) led us to consider the 
possibility that there might be a direct and general role for promoter-proximal and distal 
enhancer RNA in the binding and maintenance of TFs at regulatory elements.
We sequenced nascent transcripts (GRO-seq) in murine embryonic stem cells (ESCs) at 
great depth, which confirmed that active promoters and enhancer elements are generally 
transcribed bi-directionally (Fig. 1B, fig. S1A, table S1). We then focused our studies on the 
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TF Yin-Yang 1 (YY1) because it is ubiquitously expressed in mammalian cells, plays key 
roles in normal development, and can bind RNA species in vitro (15, 16). ChIP-seq analysis 
in ESCs revealed that YY1 binds to both active enhancers and promoters, with some 
preference for promoters (Fig. 1C, and D, fig. S1, table S2). In contrast, the pluripotency TF 
OCT4 preferentially occupies enhancers (fig. S1B). Consistent with this, YY1 sequence 
motifs were enriched at promoters, whereas OCT4 motifs were enriched at enhancers (fig. 
S1B). Neither YY1 nor OCT4 occupied the promoter-proximal sequences of inactive genes 
(fig. S2). These results establish that YY1 generally occupies active enhancer and promoter-
proximal elements in ESCs.
We next investigated YY1 binding to RNA in vivo by using CLIP-seq in ESCs (fig. S3, S4, 
table S3). The results showed that YY1 binds RNA species at the active enhancer and 
promoter regions where it is bound to DNA (Fig. 1, C and D, fig. S1C). At promoters, YY1 
preferentially occupied RNA downstream rather than upstream of transcription start sites 
(fig. S1B), consistent with YY1 motif distribution and evidence that upstream ncRNA is 
unstable (3, 17, 18). In similar experiments with OCT4, significant levels of RNA binding 
were not observed (fig. S5). These results suggest that YY1 generally binds to RNA species 
transcribed from enhancers and promoters in vivo.
The DNA and RNA binding properties of YY1 were further investigated in vitro (Fig. 2, fig. 
S6 to S8). Recombinant murine YY1 protein bound both DNA and RNA probes in 
electrophoretic mobility shift essays (EMSA), showing higher affinity for DNA than RNA. 
There was variation in the affinity of YY1 for different RNA sequences (fig. S8). The four 
YY1 zinc-fingers can bind DNA (19), but the portion of YY1 that interacts with RNA is 
unknown. The zinc-finger –containing C-terminal region and the N-terminal region of YY1 
were purified and their DNA and RNA binding properties were further investigated (fig. 
S9). The zinc-finger region of YY1 bound to DNA, but not to RNA, whereas the N-terminal 
region of YY1 bound to RNA (fig. S9). Furthermore, the DNA probe did not compete 
efficiently with the RNA probe for YY1 binding (fig. S7C, S8C). These results suggest that 
different regions of YY1 are responsible for binding to DNA and RNA.
The observation that YY1 binds to enhancer and promoter-proximal elements and to RNA 
transcribed from those regions led us to postulate that nascent RNA contributes to stable TF 
occupancy at these regulatory elements (Fig. 3A). If this model is correct, then reduced 
levels of nascent RNA at promoters and enhancers might lead to reduced YY1 occupancy at 
these sites. We briefly inhibited transcription elongation with the reversible inhibitor D-
rybofuranosylbenzimidazole (DRB) to reduce RNA levels at promoters and enhancers 
without causing changes in the steady-state levels of YY1 (fig. S10, S11). DRB treatment 
reduced transcription at promoters and enhancers and this caused small but significant 
decrease in the levels of YY1 at these regions (fig. S10). Super-enhancers are clusters of 
enhancers that are highly transcribed (20), and DRB treatment had a profound effect on 
transcription at these sites (fig. S10). Similar results were observed with additional inhibitors 
(fig. S10). When transcription was allowed to resume after DRB removal, the levels of YY1 
increased at promoters and enhancers (Fig. 3B, fig. S10A). These results suggest that 
nascent RNA produced at promoters and enhancers contributes to YY1 binding to these 
elements.
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The exosome reduces the levels of enhancer RNAs once they are released from Pol II 
(degradation is 3′ to 5′) (21), so knockdown of an exosome component will cause an 
increase in untethered enhancer RNA, which might titrate some YY1 away from enhancers. 
Indeed, exosome knockdown led to increased steady state levels of enhancer RNAs and a 
decrease in the levels of YY1 bound to enhancers (Fig. 3C, fig. S12). These results are 
consistent with the model that YY1 binding to DNA is stabilized by binding to nascent 
RNA.
If YY1 binding to DNA is stabilized by its binding to RNA, then RNase treatment of 
chromatin should reduce YY1 occupancy. Chromatin was extracted from ESC nuclei and 
the levels of YY1 in the chromatin preparation were compared with and without RNase A 
treatment (Fig. 3D). The results show that the levels of YY1 bound to chromatin were 
significantly decreased when the chromatin preparation was treated with RNase, consistent 
with the idea that RNA contributes to the stability of YY1 in chromatin.
To test the idea that RNA near regulatory elements can contribute to stable TF occupancy in 
vivo, we tethered RNA in the vicinity of YY1 binding sites at six different enhancers in 
ESCs using the CRISPR/Cas9 system and determined whether the tethered RNA increases 
the occupancy of YY1 at these enhancers (Fig. 4). We generated stable murine ESC lines 
expressing both the catalytically inactive form of bacterial endonuclease Cas9 (dCas9) and a 
fusion RNA composed of guide RNA (sgRNA), tracrRNA, and a 60-nt RNA derived from 
the promoter sequence of Arid1a compatible with YY1 binding in vitro (fig. S8). For 
controls, stable cell lines were created that express dCas9 and sgRNA fused to tracrRNA for 
the six enhancers. Tethering the Arid1a RNA at each enhancer led to increased binding of 
YY1 to the targeted enhancer as measured by ChIP-qPCR (Fig. 4B). This elevation in YY1 
binding was specific to the targeted locus and the sequence of tethered RNA as there was no 
observable increase in YY1 binding at the enhancers not targeted in the same cells (Fig. 4B) 
or targeted with tethered RNA not compatible with YY1 binding in vitro (fig. S13). These 
results show that RNA tethered near regulatory elements in vivo can enhance the level of 
YY1 occupancy at these elements.
To corroborate the in vivo RNA tethering results, a competition EMSA was used to test 
whether tethered RNA increases the apparent binding affinity of YY1 to its motif in DNA 
(fig. S14, S15). A short 30-bp labeled DNA probe containing a consensus YY1 binding 
motif was incubated with recombinant murine YY1 protein in the presence of increasing 
concentrations of cold competitor DNA with tethered or untethered RNA, and the amount of 
radiolabeled DNA that remained bound was quantified (fig. S15). This analysis revealed that 
DNA containing tethered RNA outcompetes the DNA without tethered RNA for YY1 
binding. These results indicate that tethering RNA near the YY1 binding motif in DNA 
leads to increased binding of YY1 to DNA in vitro.
In summary, our results are consistent with the proposal that RNA enhances the level of 
YY1 occupancy at active enhancer and promoter-proximal regulatory elements (Fig. 3A). 
We suggest that nascent RNA produced in the vicinity of enhancer and promoter elements 
captures dissociating YY1 via relatively weak interactions, which allows this TF to rebind to 
nearby DNA sequences, thus creating a kinetic sink that increases YY1 occupancy on the 
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regulatory element. The observation that YY1 occupies active enhancers and promoters 
throughout the ESC genome where RNA is produced, coupled with evidence that YY1 is 
expressed in all mammalian cells, suggests that this model is general. There are additional 
DNA-binding TFs that can bind RNA (fig. S16) (14), so transcriptional control may 
generally involve a positive feedback loop, where YY1 and other TFs stimulate local 
transcription, and newly transcribed nascent RNA reinforces local TF occupancy. This 
model helps explain why TFs occupy only the small fraction of their consensus motifs in the 
mammalian genome where transcription is detected and suggests that bidirectional 
transcription of active enhancers and promoters evolved, in part, to facilitate trapping of TFs 
at specific regulatory elements. The model also suggests that transcription of regulatory 
elements produces a positive feedback loop that may contribute to the stability of gene 
expression programs in cells. The significance of this TF trapping mechanism in cellular 
regulation has yet to be established, but will be important for future study because much of 
disease-associated sequence variation occurs in enhancers (20, 22) and may thus affect both 
DNA and RNA sequences that interact with gene regulators.
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YY1 binds to DNA and RNA at transcriptional regulatory elements. (A) Cartoon depicting 
divergent transcription at enhancers and promoters in mammalian cells. (B) Alignment of 
GRO-seq reads at all enhancers and promoters in ESCs. Enhancers were defined as in (23). 
The x-axis indicates distance from either the enhancer center (C) or the transcription start 
site (TSS) in kilobases. The y-axis indicates average density of uniquely mapped GRO-seq 
reads per genomic bin. (C) Gene tracks for the Arid1a gene and enhancer showing ChIP-seq 
and CLIP-seq data for bio-YY1 cells, as well as GRO-seq reads for mESCs. (D) Mean read 
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density of YY1 ChIP-seq and CLIP-seq reads at enhancers and promoters of all RefSeq 
genes in ESCs.
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YY1 binds to DNA and RNA in vitro. (A) Left panel: EMSA of YY1-DNA complexes at 
different concentrations of recombinant YY1. 5 nM of radioactively labelled 30-bp DNA 
probe derived from the promoter region of Arid1a gene containing a consensus YY1 binding 
motif (CTCTTCTCTCTTAAAATGGCTGCCTGTCTG) was incubated with increasing 
concentrations of recombinant murine YY1 protein. Right panel: EMSA of YY1-RNA 
complexes at different concentrations of recombinant YY1. 5 nM of radioactively labeled 
30-nt RNA probe derived from the same region of the Arid1a gene was incubated with 
increasing concentrations of recombinant YY1 protein. (B) Graph depicting relationship 
between the fraction of radioactively labeled DNA or RNA probe bound and the 
concentration of recombinant YY1 in the binding reaction.
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Perturbation of RNA levels affects YY1 binding to DNA. (A) Cartoon depicting hypothesis 
that RNA transcribed from regulatory elements enhances occupancy of these elements by 
TFs capable of binding both DNA and RNA. (B) (Top) GRO-seq reads (24) at promoters, 
enhancers, and super-enhancer constituents in cells before (DRB) and after release (Rel) 
from transcriptional inhibition by DRB. (Bottom) YY1 ChIP-seq reads at promoters, 
enhancers and super-enhancer constituents in cells before (DRB) and after release (Rel) 
from transcriptional inhibition by DRB. Increase in YY1 binding after release from DRB 
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inhibition is significant: p-value < 3.6x10−207 for promoters, p-value < 1.6x10−214 for 
enhancers, p-value < 9.8x10−37 for super-enhancers. (C) (Top) Box plots depicting RNA-
seq data for ribo-depleted total RNA at promoters, enhancers, and super-enhancers in ESCs 
after targeting with control (Ctrl) or Exosc3 (ExoKD) shRNA. (Bottom) Alignment of YY1 
ChIP-seq reads at promoters, enhancers and super-enhancers in ESCs after targeting with 
control (Ctrl) or Exosc3 (ExoKD) shRNA. The decrease in YY1 binding in ExoKD ESCs is 
significant: p-value < 8.1x10−9 for promoters p-value < 1.8x10−27 for enhancers, p-value < 
3.3x10−5 for super-enhancers. (D) Western blot analysis of YY1, OCT4, and histone H3 
levels in whole-cell extracts (WCE), nuclei (N), and a nuclear chromatin preparation before 
and after RNase A treatment. Histone H3 serves as a loading control and OCT4 serves as a 
negative control. Quantitation of the relative levels of YY1 and OCT4 are noted.
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Tethering of RNA adjacent an YY1 DNA binding site enhances binding of YY1 to the 
genome in vivo. (A) Strategy for tethering of RNA in the vicinity of an YY1 binding site at 
enhancers in vivo. (B) ChIP-qPCR analysis of YY1 binding at six targeted (red) and three 
not targeted (blue) enhancers in three independent experiments. The y-axis indicates fold 
change in YY1 binding in ESCs expressing the sgRNA-Arid1a RNA fusion construct 
relative to cells expressing the control sgRNA targeted to the same locus. The difference in 
YY1 binding was significant for the targeted enhancers: Klf5 (p-value=0.03), Suz12 (p-
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value=0.01), E2f3 (p-value=0.01), Nufip2 (p-value=0.03), Cnot6 (p-value=0.03), and Pias1 
(p-value=0.01), but not for the not targeted enhancers.
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